Tweet
Just wondering if anyone have seen the same problem with cycle 30.
Thanks,
Victor
Thanks,
Victor
-
-
it's not normal. This is for a single run? If you have the images look at the images, see if they get dimmer or something else strange happens at cycle 30. If you don't have the images then look at the intensity plots, do you have a significant drop in average intensity around cycle 30? What do the error rates for cycle 30+ look like on the control lane? -
This is Solexa, right?
If it is, maybe you would like to look at that
maybe you would like to look at that:
Substantial biases in ultra-short read data sets from high-throughput DNA sequencing. 2008, July. Nucl. Acids Res.
[]s
glacerdaComment
-
I already posted this answer in the other thread where you asked about this, but I thought I'd post it here as well. This is possibly an artifact of the Illumina pipeline quality score normalization rather than an actual sudden drop in quality.
This is most likely because the qualities you are looking at are alignment normalized, and a large number of your sequences failed to align to the reference genome (due to a ligated adapter, etc.)
Take a look at the un-normalized scores (s_<lane>_qraw.txt) instead, I think you'll find that the curve is more continuous between cycles.@1
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
+
""""""""""""""""""""""""""""""""""""Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment